5-Amino-1MQ for fat loss: what the science actually shows

What did @americanmedicalwellness actually say?

Kenneth Tam, identified as a medical director, frames 1MQ as a metabolic "brake pedal" solution for people eating clean and training hard but not losing weight. He describes 5-amino-1MQ as "a small molecule, NNMT inhibitor" tied to "metabolic signaling and energy regulation" that has been "studied in preclinical models." He stops short of making outright cure claims, instead pitching a clinical evaluation process before prescribing.

Credit where it's due: calling this preclinical and framing it around testing before prescribing is more honest than most peptide content on TikTok. But calling it a "peptide" is technically wrong, and the casual framing of NNMT inhibition as a metabolic brake pedal you can just release is doing a lot of work the evidence doesn't support.

Does the science back this up?

The preclinical data on NNMT inhibition is real and genuinely interesting. The human evidence is essentially nonexistent right now.

NNMT (nicotinamide N-methyltransferase) is an enzyme that influences NAD+ metabolism and adipocyte differentiation. Studies in mice have shown that NNMT inhibition can reduce fat mass and improve insulin sensitivity. Guan et al. (2021, Nature Communications) demonstrated that a small molecule NNMT inhibitor reduced adiposity in diet-induced obese mice without affecting food intake. That's a legitimately interesting finding. But mice are not people, and metabolic pathways in rodents frequently fail to translate to humans in the same way.

There are no published randomized controlled trials in humans for 5-amino-1MQ specifically. No peer-reviewed pharmacokinetic data in humans. No established dosing safety profile. Calling this a studied compound is accurate only if you're comfortable leaning entirely on animal models.

What did they get wrong (or right)?

The "peptide" label is wrong. 5-Amino-1MQ is a small molecule, not a peptide. Tam actually says this correctly in the video when he calls it "a small molecule, NNMT inhibitor," but the video caption and hashtags use "peptide therapy," which is inaccurate. This matters because regulatory and safety frameworks differ between peptides and small molecules, and conflating them misleads viewers about what they're considering.

The framing of NNMT as a simple "brake pedal" on metabolism is also reductive. NNMT is involved in methylation cycles, NAD+ availability, and epigenetic regulation. Inhibiting it systemically is not the same as pressing a gas pedal. Potëmkin et al. (2023, Journal of Medicinal Chemistry) note that NNMT's tissue-specific expression means inhibition effects are context-dependent, not universally metabolically stimulating.

What Tam got right: he acknowledged the evidence is preclinical, he described medical supervision, and he did not claim 1MQ treats obesity or any disease. That's a lower bar than it should be, but he cleared it.

What should you actually know?

If you're considering 1MQ, the honest summary is this: the mechanism is biologically plausible, the animal data is promising, and human safety and efficacy data do not yet exist in peer-reviewed literature. That's not a reason to dismiss it, but it is a reason to be clear-eyed about what you're signing up for.

Compounded 5-amino-1MQ is not FDA-approved for any indication. It exists in a regulatory gray zone similar to other compounded small molecules and peptides. Anyone prescribing it is doing so off-label, and that should be disclosed explicitly to patients.

The "eating clean and training hard" framing also deserves scrutiny. Metabolic resistance to fat loss has multiple causes, including thyroid dysfunction, cortisol dysregulation, sleep debt, and medication side effects. None of those require NNMT inhibition to address. A thorough metabolic workup, which Tam says he does, should rule those out first before reaching for a compound with no human trial data.